OECD Updated and Corrected Testing Guidelines
The Organisation for Economic Co-operation and Development (OECD) is an international organisation that works on “establishing evidence-based international standards and finding solutions to a range of social, economic and environmental challenges”. The OECD has updated and corrected eight OECD Test Guidelines, in order to continue ensuring chemicals safety and keep up with scientific progress for OECD members and Mutual Acceptance of Data (MAD) adhering countries.

OECD AND ITS TEST GUIDELINES 

The Organisation for Economic Co-operation and Development (OECD) assists countries in harmonising Guidelines for the testing of chemicals and Good Laboratory Practice. Its main goal is to ensure high quality and reliable data. The OECD Mutual Acceptance of Data (MAD) system is the major tool to reach this harmonization on chemical regulation. The MAD system includes the OECD Guidelines for the Testing of Chemicals and OECD Principles of Good Laboratory Practice (GLP). 

The OECD Guidelines for the testing of chemicals are a set of 105 of the most relevant internationally agreed methods used by governments, industry and independent laboratories to assess the safety of chemicals.  

The OECD Guidelines are divided into 5 sections:  

  • Section 1: Physical Chemical Properties. 
  • Section 2: Effects on Biotic Systems (Software for TG 223). 
  • Section 3: Environmental Fate and Behaviour (Software for TG 305 and TG 318). 
  • Section 4: Health Effects (Software for TG 455, TG 432 and TG 425). 
  • Section 5: Other Test Guidelines. 

On June 26, 2020, the OECD updated and corrected eight Test Guidelines, including 6 in vitro and in chemico test guidelines, widely used in cosmetic ingredients testing.  

The Test Guidelines updated are: 

  • Test No. 437: Bovine Corneal Opacity and Permeability Test Method for Identifying i) Chemicals Inducing Serious Eye Damage and ii) Chemicals Not Requiring Classification for Eye Irritation or Serious Eye Damage. 
  • Test No. 458: Stably Transfected Human Androgen Receptor Transcriptional Activation Assay for Detection of Androgenic Agonist and Antagonist Activity of Chemicals. 
  • Test No. 488: Transgenic Rodent Somatic and Germ Cell Gene Mutation Assays. 
  • Test No. 491: Short Time Exposure In Vitro Test Method for Identifying i) Chemicals Inducing Serious Eye Damage and ii) Chemicals Not Requiring Classification for Eye Irritation or Serious Eye Damage. 

The Test Guidelines corrected are: 

  • Test No. 405: Acute eye Irritation/Corrosion 
  • Test No. 439: In Vitro Skin Irritation: Reconstructed Human Epidermis Test Method 
  • Test No. 422C: In Chemico Skin Sensitisation. 
  • Test No. 471: Bacterial Reverse Mutation Test. 

The OECD Test Guidelines are indispensable for regulatory safety testing and subsequent chemical and chemical product notification, chemical registration and in chemical evaluation. They can also be used in toxicology research and for the selection and ranking of candidate chemicals through the development of new chemicals and products. 

References: 

  1. Organisation for Economic Co-operation and Development (OECD). Disponível em: http://www.oecd.org/ 

further
reading

medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
parfum_fragrance_allergen_1
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »